Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Xilio Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 33
- +2 vs. Q2 2024
- Shares held
- 16.0M
- +1.51M (+10.5%) vs. Q2 2024
- Total value
- $12.6M
- −$1.10M (−8.1%) vs. Q2 2024
- New holders
- 6
- 8 more added
- Sold out
- 4
- 4 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 75 | $59 | 0.00% | +16+27.1% | Added |
| Bank of America Corp | 266 | $209 | 0.00% | −426−61.6% | Reduced |
| Private Wealth Management Group, LLC | 310 | $245 | 0.00% | +310 | New |
| Key Financial Inc | 830 | $654 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,616 | $4.42K | 0.00% | +1,409+33.5% | Added |
| Pinnacle Financial Group, LLC | 10,000 | $7.88K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $8.09K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 10,389 | $8.18K | 0.00% | +10,389 | New |
| UBS Group AG | 15,733 | $12.4K | 0.00% | +15,532+7,727.4% | Added |
| Steward Partners Investment Advisory, LLC | 20,000 | $15.8K | 0.00% | +20,000 | New |
| Avantax Planning Partners, Inc. | 20,483 | $16.1K | 0.00% | −4,517−18.1% | Reduced |
| Millennium Management LLC | 20,655 | $16.3K | 0.00% | +8,450+69.2% | Added |
| XTX Topco Ltd | 23,862 | $18.8K | 0.00% | −9,427−28.3% | Reduced |
| Mariner, LLC | 25,317 | $19.9K | 0.00% | +25,317 | New |
| Engineers Gate Manager LP | 32,752 | $25.8K | 0.00% | +32,752 | New |
| Raymond James & Associates | 38,825 | $30.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 39,208 | $30.9K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 43,390 | $34.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 44,445 | $35.0K | 0.00% | +31,174+234.9% | Added |
| SevenBridge Financial Group, LLC | 41,000 | $44.7K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 71,081 | $56.0K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 75,624 | $59.6K | 0.00% | +75,624 | New |
| FIL Ltd | 218,705 | $172.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 266,300 | $209.8K | 0.00% | −28,700−9.7% | Reduced |
| Balyasny Asset Management LLC | 272,486 | $214.6K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 338,192 | $266.4K | 0.00% | +155,337+85.0% | Added |
| Vanguard Group Inc | 902,531 | $711.2K | 0.00% | 00.0% | Unchanged |
| FMR LLC | 1,395,853 | $1.10M | 0.00% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $1.14M | 16.60% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.16M | 3.06% | 00.0% | Unchanged |
| Morgan Stanley | 1,522,102 | $1.20M | 0.00% | +409,362+36.8% | Added |
| Rock Springs Capital Management LP | 3,003,259 | $2.37M | 0.08% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.60M | 0.37% | +781,367+20.6% | Added |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −11,925−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −366−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |